IV immunoglobulin does not reverse established weakness in MS: A double-blind, placebo-controlled trial

Neurology

Volumn 55, Issue 8, 2000, Pages 1135-1143

  Noseworthy, John H ^a   O'Brien, P C ^a   Weinshenker, B G ^a   Weis, J A ^a   Petterson, T M ^a   Erickson, B J ^a   Windebank, A J ^a   Whisnant, J P ^a   Stolp Smith, K A ^a   Harper Jr , C M ^a   Low, P A ^a   Romme, L J ^a   Johnson, M ^a   An, K N ^a   Rodriguez, M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATING DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; HEADACHE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MUSCLE STRENGTH; MUSCLE WEAKNESS; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME;

EID: 0034711155     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.55.8.1135     Document Type: Article

References (51)

1. Studies on the natural history of multiple sclerosis: 7. Correlates of clinical change in an early bout
2. Immunoglobulins promote remyelination in the central nervous system
3. Immune promotion of central nervous system remyelination
4. Immunoglobulins reactive with myelin basic protein promote CNS remyelination
5. Monoclonal autoantibody SCH94.03, which promotes central nervous system remyelination, recognizes an antigen on the surface of oligodendrocytes
6. A monoclonal autoantibody which promotes central nervous system remyelination is highly polyreactive to multiple known and novel antigens
7. Promotion of remyelination by polyclonal immunoglobulin and IVIg in Theiler's virus induced demyelination and in MS
8. First results of immunotherapy with immunoglobulin G in multiple sclerosis patients
9. High-dose intravenous immunoglobulin for multiple sclerosis
10. Improved vision after intravenous immunoglobuFln in stable demyelinating optic neuritis
11. Intravenous immunoglobulin therapy in multiple sclerosis: Progress from the Thefier's virus model to a randomized, double-blinded, placebo-controlled clinical trial
12. Clinical evaluation of motor function
13. Treatment of stable chronic demyelinating polyneuropathy with 3,4-diaminopyridine
14. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome
15. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple scierosis
16. Quantitative assessment of motor fatigue and strength in MS
17. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
18. Defining the clinical course of multiple sclerosis: Results of an international survey
19. The efficacy of azathioprine in relapsing-remitting multiple sclerosis
20. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis
21. Overview of azathioprine treatment in multiple sclerosis
22. Predicting short- and long-term worsening of disability in MS patients
23. Rating neurological impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS)
24. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH
25. The Mayo Clinic Canadian Cooperative Trial of Sulfasalazine in active multiple sclerosis
26. Performance profiles of the functional independence measure
27. Upper extremity function in multiple sclerosis: Improving assessment sensitivity with box-and-block and nine-hole peg tests
28. Reliability of isometric strength testing
29. Isometric elbow strength in normal individuals
30. Objective evaluation of hand function in scleroderma patients to assess effectiveness of physical therapy
31. A quantitative analysis of donor site morbidity after vascularized fibula transfer
32. Quantitative measurements of hip strength in different age groups
33. The relationship of strength and jump height in figure skaters
34. Shoulder strength analysis using the Cybex II isokinetic dynamometer
35. Magnetization transfer effects in MR-detected multiple sclerosis lesions: Comparison with gadolinium-enhanced spin-echo images and nonenhanced T1-weighted images
36. An algorithm for automatic segmentation and classification of magnetic resonance brain images
37. Intravenous immunoglobulins in multiple sclerosis
38. Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases
39. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses
40. A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: Preliminary results
41. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis
42. Combined immunoglobulin and azathioprine in multiple sclerosis
43. Randomised placebo-controlled trial of monthly intravenous immfinoglobulin therapy in relapsing-remitting multiple sclerosis
44. Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: Further analyses of the Austrian Immunoglobulin in MS study
45. Intravenous gamma globulin in progressive MS
46. Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: A clinical and MRI based study
47. Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis - Outline of a double-blind randomized, placebo-controlled trial
48. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study
49. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensiive MRI method with potential to monitor disease progression
50. A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)